Loading...
Valneva SE
INRLF•PNK
Healthcare
Biotechnology
$3.91
$0.06(1.56%)
Valneva SE (INRLF) Financial Performance & Income Statement Overview
Review Valneva SE’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
10.32%
↑ 10.32%
Operating Income Growth
116.24%
↑ 116.24%
Net Income Growth
87.93%
↑ 87.93%
Operating Cash Flow Growth
66.85%
↑ 66.85%
Operating Margin
-32.70%
↓ 32.70%
Gross Margin
37.67%
↑ 37.67%
Net Profit Margin
-43.21%
↓ 43.21%
ROE
-43.44%
↓ 43.44%
ROIC
-16.18%
↓ 16.18%
Valneva SE (INRLF) Income Statement & Financial Overview
Review Valneva SE's (INRLF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $52.94M | $45.82M | $38.06M | $32.75M |
| Cost of Revenue | $27.23M | $25.68M | $23.47M | $22.16M |
| Gross Profit | $25.71M | $20.15M | $14.59M | $10.59M |
| Gross Profit Ratio | $0.49 | $0.44 | $0.38 | $0.32 |
| R&D Expenses | $25.58M | $18.88M | $16.55M | $13.13M |
| SG&A Expenses | $26.83M | $22.24M | $23.02M | $23.003M |
| Operating Expenses | $46.59M | $32.59M | $36.14M | $36.13M |
| Total Costs & Expenses | $73.83M | $58.27M | $59.60M | $58.29M |
| Interest Income | $1.05M | $529000.00 | $521000.00 | $266000.00 |
| Interest Expense | $6.27M | $5.73M | $4.94M | $7.04M |
| Depreciation & Amortization | $0.00 | $5.22M | $1.38M | $2.94M |
| EBITDA | -$26.08M | -$7.22M | -$20.16M | -$22.36M |
| EBITDA Ratio | -$0.49 | -$0.16 | -$0.53 | -$0.68 |
| Operating Income | -$20.88M | -$12.45M | -$21.55M | -$25.54M |
| Operating Income Ratio | -$0.39 | -$0.27 | -$0.57 | -$0.78 |
| Other Income/Expenses (Net) | -$11.46M | -$507000.00 | -$3.56M | -$9.29M |
| Income Before Tax | -$32.35M | -$12.96M | -$25.10M | $58.92M |
| Income Before Tax Ratio | -$0.61 | -$0.28 | -$0.66 | $1.80 |
| Income Tax Expense | $4.64M | -$3.72M | -$167000.00 | $9000.00 |
| Net Income | -$36.99M | -$9.24M | -$24.93M | $58.91M |
| Net Income Ratio | -$0.70 | -$0.20 | -$0.66 | $1.80 |
| EPS | -$0.25 | -$0.07 | -$0.19 | $0.42 |
| Diluted EPS | -$0.25 | -$0.07 | -$0.19 | $0.42 |
| Weighted Avg Shares Outstanding | $162.40M | $131.55M | $131.55M | $138.79M |
| Weighted Avg Shares Outstanding (Diluted) | $162.40M | $131.55M | $131.55M | $138.79M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan